Oregon State University logo

Marketed Unapproved Drugs Webinar – May 2

The Food and Drug Administration, Center for Drug Evaluation and Research (CDER), is delighted to inform you of a unique opportunity for healthcare professionals, pharmacy students, and medical students in the United States to learn more about the FDA and drug regulation.

CDER’s Division of Drug Information (DDI) is offering a series of educational webinars, developed by FDA pharmacists and targeted to the needs of all healthcare professionals and students. These focused webinars support FDA’s mission of promoting and protecting public health, through interaction and education to strengthen relationships with future clinicians, researchers, and pharmacists. Fostering this connection will provide a better understanding of FDA’s role in public health as a regulatory agency.

On May 2, 2011, at 11 a.m. (ET), CDER’s Office of Compliance, Division of New Drugs and Labeling Compliance (DNDLC) will present a webinar titled, “Marketed Unapproved Drugs.” Lori Cantin, R.Ph., Pharm.D., will present an overview of the history of drug regulation in the United States, discuss the public health risks associated with marketed, unapproved drugs and FDA’s Unapproved Drug Initiative, and will identify tools to assist in determining the approval status of prescription drug products.

To join the meeting May 2nd:

1. Click the following URL https://collaboration.fda.gov/eigprogram/(or cut and paste it into your internet browser).

2. Click on the “Enter as a Guest” button, fill in your name, and then click “Enter Room.” Materials from the webinar will also be available on the FDA website.

Please direct your comments or questions via email to Kara Daniel, Pharm.D., kara.daniel@fda.hhs.gov

Comments are closed.